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Introduction
Radiochemistry is one of the most powerful and versatile
tools for studying chemical processes at sub-nanomolar levels.
Radiolabelled compounds find widespread applications, particu-
larly in Nuclear Medicine as both diagnostic imaging agents and
targeted radiotherapeutics. Defining features of working with un-
stable radionuclides include the half-life and the decay modes.
In our group, we primarily work with metal-based radionuclides
with half-lives spanning a few minutes to several hours (Fig. 1).
Our research focuses on the development of novel radiotracers
for use in positron emission tomography (PET) imaging of var-
ious cancer biomarkers. Radiotracer development requires an
multidisciplinary approach, from organic synthesis, coordination
chemistry, inorganic biochemistry, and radiochemistry through to
molecular imaging in vivo. In addition, we explore new conjuga-
tion methods and radiochemical reactions for introducing radio-
nuclides to a diverse range of biologically active materials from
small drug molecules, peptides and proteins, through to nanopar-
ticles. We also perform complete biochemical characterisation of
our most promising radiotracers in vitro and imaging studies in
tumour-bearing animal models. Collectively, these experiments
provide the essential scientific foundation for clinical translation
of new radiotracers (Fig. 2).
Radiochemical synthesis lies at the heart of all successful
radiopharmaceuticals. Traditional organic and inorganic chemis-
try offer many elegant reactions that can be adapted for use in
radiochemistry but reaction rate is a critical consideration. Our
radioactive stock solutions contain, at best, a few nanomoles of
the radionuclide and due to the relatively short half-lives, all ra-
diochemical reactions and characterisation should be complete
within a few hours from the start of synthesis. Hence, radiochem-
ical kinetics play a central role in determining the success of any
labelling process. Our recent concept article provided the first rig-
Fig. 1. Radionuclides employed in our group for the development of
alternative radiolabelling methods and the synthesis of radiotracers for
applications in imaging and therapy.
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that the metal ion binding occurs via a mechanism associated with
surface (radio)mineralisation (Fig. 3).[11,12]
Chelate-free radiolabelling offers a fast and efficient route for
introducing different radioactive metal ions onto metal-based na-
noparticles. In this context, we continue to explore the mechanism
and surface-based reactivity using kinetic studies (Fig. 4), as well
as head-to-head comparisons of chelate-free radiochemistry with
more traditional labelling methods for use in the development of
cancer-targeted iron oxide nanoparticles for multi-modality PET/
magnetic resonance imaging (MRI) of tumours. Experimental
work encompasses the synthesis of different nanoparticles with
controlled size, composition and coatings (Fig. 5). Nanoparticles
are extremely challenging materials to study, but an emerging
trend is that surface-reactivity can be exploited for simultaneous
radiolabelling and functionalisation with various drug molecules,
cancer-specific ligands, and other (optically active) reporter
probes. Our general experience is that multi-modality probes can
be constructed and show positive tumour-specific binding in vit-
ro, although controlling the pharmacokinetics of the particles in
vivo remains a challenge. To this end, we are exploring the use of
different coating materials, stabilisers, and protein-based interac-
tions to identify alternative ways of shielding these nanoparticles
from non-specific clearance by the reticuloendothelial system.
orous formulation of equations and parameters to consider when
using chemical kinetics in the context of radiosynthesis.[1] What
emerges from the constraints of working with short-lived radio-
nuclides at low concentrations is the notion that faster reactions
are required to minimise reaction times and maximise the activity
yield.At the same time, when usingmetal radionuclides, reactions
should be compatible with aqueous formulation buffers. In this
context, our group is exploring a wide range of alternative meth-
ods for constructing multi-functional radiotracers. The following
sections provide a brief overview of our ongoing projects that
utilise surface-based chemistry, photochemistry, and supramolec-
ular chemistry as novel routes toward radiotracer synthesis. In
addition, a core feature of our work withmetal radionuclides is the
synthesis of new ligands for building metal ion complexes with
controlled coordination spheres, high thermodynamic and kinet-
ic stability, and reactive handles for bioconjugation to various
cancer-targeting vectors (particularly antibodies). Computational
studies with density functional theory (DFT) are used to gain a
deeper understanding of the chemistry, electronic structure and
spectroscopy of various metal ion complexes, as well as probe
reaction mechanisms and streamline our synthetic targets.
Surface-based Radiochemistry and Multi-modality
Nanoparticles for Imaging and Therapy
Nanoparticles are interesting platforms for developing multi-
modality imaging agents. For example, Bradbury and co-workers
reported the clinical translation of 124I-radiolabelled ultrasmall in-
organic hybrid nanoparticles (C-dots) that offer combined PET and
optical imaging options.[2]However, efficientmethods for introduc-
ing radioactive nuclides without perturbing the physicochemical
properties of the particles is one of the main limitations advancing
nanomedicines to the clinic. Traditional methods for labelling nan-
oparticles rely on the use of metal ion binding chelates or prosthetic
groups.[3,4] In 2013, pioneering studies from the group ofWeibo Cai
demonstrated that the intrinsic reactivity of metal oxide nanoparti-
cles can be used to bind radioactive metal ions with high stability
and rapid labelling kinetics.[5] In 2015, our group expanded on this
initial concept by demonstrating the scope of chelate-free labelling
of iron oxide-based nanoparticles using 64Cu, 89Zr and 111In radionu-
clides, as well as various non-radioactivemetal ions from across the
p-, d- and f-blocks.[6] Subsequent studies have used the chelate-free
approach with a wide range of nanoparticles[7–10] and recent exper-
imental work has supported our initial observations and hypothesis
Fig. 2. An overview of the
main work-flow in our group.
Experimental and computational
design, synthesis, and complete
characterisation is performed in
house, with international collab-
orations facilitating clinical trans-
lation.
Fig. 3. Illustration of different particle-based binding modes for the che-
late-free (intrinsic) radiolabelling of nanoparticles with various radioactive
metal ions.[6,12]
Fig. 4. Kinetic studies on the in-
trinsic metal ion radiolabelling of
Fe3O4 nanoparticles by surface
(radio)mineralisation. (Left) A sche-
matic of the reaction and various
parameters tested in the kinetic
studies. (Right) Experimental data
showing the percentage radi-
ochemical conversion versus time
for 68Ga-radiolabelling of Fe3O4
NPs.
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constant, log β) are a primary arbiter in determining the relative
complexation power of one ligand versus another. The problem
is that classic methods such as potentiometric titration and iso-
thermal calorimetry are often not accessible when working with
high-valent (e.g. Ga3+, Zr4+) metal ion complexes that exhibit for-
mation constants >30. Therefore, direct comparison of chelates
reported by different research groups presents a challenge. To
address this issue, we developed a computational approach for
estimating both the relative and absolute thermodynamic stabil-
ity of different chelates.[14] DFT calculations have proved useful
in assisting the design of chelates for 89Zr4+ ions which require
extremely hard Lewis acid donor sets. Recently our group has
shifted direction to explore the coordination chemistry of the
extremely soft arsenite (As3+) cation. At first sight, arsenic may
not appear an obvious choice for developing radiotracers and the





is an approved therapy for treating leukaemia.At the tracer
level, the inherent toxicity of As is not a factor in the dosimetry.
Arsenic has at least five radionuclides with potential applications
in imaging and therapy: 71As (t
1/2





= 17.77 d) decay via β+-emission, whereas 74As,
76As (t
1/2
= 26.24 h), 77As (t
1/2
= 38.79 h) emit β––particles that
are suitable for radiotherapy. The concept of a matched-pair of
radionuclides for applications in imaging and therapy is a driving
force for developing As-based radiotracers. Access to new che-
lates for complexation of As3+ ions would facilitate radiotracer
development.
In addition, our synthetic work explores new routes toward
multi-dentate aza-macrocycles bearing mixed, N,S,O donor sets
for the metal ion selective complexation of Ga3+ and Cu2+ ions. To
expand the potential applications of our new chelates for use in
radiotracer synthesis and PET imaging, we are synthesising vari-
ous small-molecule vectors for selective binding to the fibroblast
activation protein (FAP) and as potent ‘theranostics’ for targeted
imaging and therapy of prostate cancer via binding to the prostate
specific membrane antigen (PSMA) (Fig. 8).
Through an active collaboration with the group of Christoph
Salzmann (University College London, UK), we have also ex-
panded our efforts to synthesise multi-modality PET/MRI agents.
Here,wecombinediagnosticand therapeutic (‘theranostic’) agents
by using graphene nanoflakes (GNFs; Fig. 6) as scaffolds.[13]
Initial studies demonstrated that GNFs could be functionalised
withmultiple ligands at the carboxylated edge via amide bond for-
mation. Subsequent chemical and biochemical assays, including
zeta potential and lipophilicity measurements, dynamic light scat-
tering, transmission electron microscopy, radiolabelling, cellular
binding and antiproliferation measurements, as well as dynamic
PET imaging in vivo are used to investigate the different features
of these complex systems. Initial efforts to target cancer biomark-
ers using small-molecule ligands proved successful in vitro, but
again yielded poor pharmacokinetics with rapid excretion via the
renal system. Our latest studies are tackling the issue of extending
the blood pool circulation time and promoting tumour-specific
uptake in vivo by targeting multi-functional GNFs (bearing radio-
nuclides, Gd-basedMRI probes and optically active fluorophores)
with various antibodies.
New Ligands for Radiometal Ions and Applications in
Radiotracer Synthesis
Coordination chemistry is a central tenet of metal-based radi-
ochemistry. Our group is active in this field and we focus primar-
ily on the computational design, synthesis and characterisation
of new chelates for complexation of Cu2+, Ga3+, Zr4+ and As3+
cations (Fig. 7). Although the overall stability of a radiometal
ion complex in vivo is dependent on kinetic and metabolic fac-
tors, thermodynamic parameters (as illustrated by the formation
Fig. 5. Synthesis and characterisa-
tion of cancer-specific super para-
magnetic iron oxide nanoparticles
bearing different surface coatings.
Surface functionalisation strat-
egies employ several anchoring
groups to modify particle loading
and stability.
Fig. 6. Schematic structure of a multi-functional graphene nanoflake
(GNF) bearing a Gd3+-complex for MRI, a 68Ga-complex for PET, a pros-
tate cancer-specific vector targeting PSMA, and a potent antimitotic
drug (R)-ispinesib capable of inducing mitotic phase arrest by allosteric
inhibition of kinesin spindle protein (KSP; hsEg5).
Fig. 7. Representative structures of new chelates for potential complex-
ation of radioactive metal ions including 64Cu2+, 68Ga3+, 89Zr4+, and various
radionuclides of *As3+.
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diosynthesis of 89Zr-mAbs for use in the clinic. As our technology
develops, we hope that more groups will become interested in ex-
ploring the use of photochemistry for making protein conjugates
including radiotracers and antibody-drug conjugates (ADCs)
with a wider selection of covalent bioconjugate bonds. In the next
step, we aim to explore the chemical scope of light-induced re-
actions by synthesising a range of ligands with photoactivatable
moieties that generate (among other species), stabilised singlet
nitrenes, carbenes, diradicals, and nitrile imines (Fig. 10).[21]
We have also introduced photochemically active fluorophores for
tagging proteins (PhotoTags). The synthesis and exploration of
the photophysical properties of several different classes of fluoro-
phores are ongoing topics within the group.[26]
Supramolecular Chemistry in Radiotracer Design
In keeping with our theme of developing alternative fast re-
actions to access radiolabelled constructs with complex architec-
tures, we began exploring the use of supramolecular chemistry in
radiotracer design (Fig. 11). Building on a fascinating reaction
from Mock et al.,[27] we have adapted Stoddart’s ‘cooperative
capture’ concept[28] to synthesise the first radiolabelled rotaxanes.
Multi-component reactions involving up to 5 different compounds
and 7 functional units in total have been successfully developed to
produce several different rotaxanes targeted toward prostate can-
cer. Molecular features include the use of acyclic and aza-macr-
ocyclic chelates for selective complexation of 68Ga and 89Zr radi-
onuclides, and fluorophores as stoppers on the axel; functionali-
sation of the cyclodextrin host with cancer-targeting vectors, and
metal ion complexes; and stoichiometric control allowing the syn-
thesis of symmetric and asymmetric rotaxanes. Remarkably, this
complex, multi-component chemistry is performed in water and
we are currently evaluating the properties of several compounds in
vitro and in vivo. At this stage, our research remains fundamental
but the ultimate goal is to advance this supramolecular technology
as a means of fine-tuning the pharmacokinetic profiles of radio-
tracers via site-selective metabolism and controlled drug release
to minimise radiation burden in off-target tissues.
Applications of Photochemistry in Protein-Ligation
and Radiotracer Synthesis
A centrepiece of our recent work is the demonstration that
extremely fast, light-induced reactions can be controlled for che-
moselective, bimolecular functionalisation of proteins (particu-
larly antibodies [mAbs]).[15–22] The general concept is captured
in Fig. 9 and involves the synthesis of photoactivatable metal ion
binding chelates, optical probes or potent drug molecules for the
one-pot functionalisation ofmAbs at room temperature undermild
UV irradiation. As an example, the photolysis of aryl azides with
light at 365–395 nm induces efficient activation via the loss of
N
2
(g) and yields an extremely reactive (life-time ~1 ns) open-shell
singlet nitrene. This reaction is well-known and has been utilised
in photoaffinity labelling.[23,24] However, in our work, we estab-
lished conditions whereby the photo-induced products rearrange
to a powerful ketenimine electrophile that, remarkably, undergoes
kinetically favourable reactions with primary amines. This allows
fast, efficient, and chemoselective functionalisation of lysine res-
idues on a protein over background quenching reactions in aerated
water. Detailed experimental, spectroscopic, radiochemical and
computational studies have allowed us to probe the mechanism
and further develop the method. Unlike other standard reagents
that are used for protein ligation including activated esters, ben-
zyl-isothiocyanates and maleimides, photochemistry can be used
to functionalise mAbs in formulation buffers (common additives
include amino acids, ascorbic acid, sugars and other surfactants).
Furthermore, unlike traditional bioconjugation methods which
may require multiple steps and extended reaction times,[25] the
photochemically induced bioconjugation reactions were found to
be first-order in light intensity and are typically complete in <15
min. Collectively, these features of highly tolerant chemistry and
extremely rapid kinetics at radiotracer concentrations mean that
we can now develop fully automated radiosynthesis units for ac-
cessing 89Zr-mAbs directly from clinical-grade protein samples.
Automation would circumvent the need for multiple purification
steps, and the expensive synthesis, isolation, characterisation
and long-term storage of a functionalised protein-intermediate.
Current efforts includework toward the translation of our photora-
Fig. 8. Small-molecule radiola-
belled ‘theranostics’ that can
combine diagnostic imaging with
target-specific chemotherapy.
Fig. 9. Schematic illustration of light-induced bimolecular protein-conjugation and photoradiosynthesis of 89Zr-mAbs with successful tumour target-
ing monitored by PET.
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Transmetallation Chemistry and Fluoride Anion
Capture
Other avenues of ongoing research include the development
of transmetallation reactions for radiolabelling 64Cu complexes
starting from the non-radioactive Zn2+ precursor species with mil-
lisecond kinetics (Fig. 12). This work builds on a concept that was
first introduced by the Dilworth group,[29] and our efforts include
exploring the chemical scope of transmetallation using different
chelates and also different radionuclides. In addition, the aim is
to adapt this promising method for the synthesis and validation of




= 109.7 min) is the most common radionu-
clide used in the development of PET radiotracers. Building on
pioneering reports from McBride et al.,[30] which demonstrated
that fluoride anions can be captured and incorporated into the
structure of Al3+ aza-macrocyclic complexes via the formation of
a strongAl-F bond, we are exploring the chemical scope of metal–
fluoride bond formation. Our principle objective is to combine 18F
with high-valent, non-radioactive Zr4+ complexes as a new route
toward the synthesis of small-molecule and peptide-based radi-
otracers via the direct, aqueous-phase capture of 18F from target
solutions (Fig. 13). Successful direct 18F capture would avoid the
time consuming anion trapping and azeotropic drying steps that
are a feature of most organic 18F radiochemistry. Current experi-
ments focus on the synthesis of bifunctional ligands that provide
thermodynamically selective and stable complexation of Zr4+
ions, yet feature a vacant site in the first coordination sphere that
can accept a fluoride anion selectively in the presence of other
Fig. 10. A selection of photoactivatable DFO derivatives bearing different
light-responsive groups.
Fig. 11. Supramolecular
approaches toward the rapid
synthesis of cancer-specific dual-
modality imaging agents.
Fig. 12. Rapid 64Cu-radiolabelling
by transmetallation.
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putational design of new coordination complexes, and the study
of biological processes in vitro and in vivo, all with the ability to
deliver essential diagnostic and therapeutic tools for application
in Nuclear Medicine. The general philosophy of our research is
that the multidisciplinary facets of radiochemistry should not be
decoupled but rather, embraced to provide a more complete char-
acterisation and mechanistic understanding of the radiochemical
methods and biochemical tool that we develop. Radiochemistry
has a bright future ahead.
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